DPEP-1 Binding Compositions and Methods of Use
AssigneeArch Biopartners, Inc.
InventorsStephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing SZE Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
Claims35
A method for treating inflammation in a subject in need thereof, comprising administering an effective amount of a compound that binds to DPEP-1 to the subject, thereby treating inflammation.
A method for block leukocyte recruitment in a subject in need thereof, comprising administering an effective amount of a composition that binds to DPEP-1 to the subject, thereby blocking leukocyte recruitment.
A method for reducing or preventing tumor metastasis in a subject in need thereof, comprising administering an effective amount of a DPEP-1 binding agent, thereby reducing or preventing tumor metastasis.
A method for treating or preventing organ damage associated with sepsis in a subject in need thereof, comprising administering an effective amount of a composition that binds to DPEP-1 to the subject, thereby reducing or preventing organ damage associated with sepsis.
A method for treating or preventing acute kidney injury in a subject in need thereof, comprising administering an effective amount of a composition that binds to DPEP-1 to the subject, thereby reducing or preventing acute kidney injury.
A method for treating or preventing ischemia-reperfusion injury in a subject in need thereof, comprising administering an effective amount of a composition that binds to DPEP-1 to the subject, thereby reducing or preventing ischemia-reperfusion injury.
A method for identifying a compound that inhibit inflammation, comprising:
- (a) screening a library of test compounds for their ability to bind to DPEP-1 in a tissue;
- (b) selecting test compounds that show selective binding affinity, thereby providing candidate compounds;
- (c) testing the candidate compounds for inflammation inhibiting activity;
- and (d) selecting a candidate compound if it inhibits inflammation, thereby providing a compound that inhibits inflammation.
Dependencies are inferred from the claim text.